Market News AIOpen the app

CG Oncology's bladder cancer trial worked well, lowering the chance of cancer coming back.

TrialRead the original at Benzinga
Good for CGON

CG Oncology's Phase 3 study cut cancer recurrence risk by 68%, and reported no Grade 3 or higher treatment-related events. The drug still needs FDA approval, and the company plans to file applications in 2027.

CGON · CG Oncology Inc.

AI read · Good for CGON

The AI's read

The trial gives CG Oncology strong evidence that its bladder-cancer drug can delay cancer returning, with few serious treatment problems reported. The company plans FDA applications in 2027, but the drug is not approved yet. The trial results still make the company's path forward look stronger.

Get alerts for CGON

Follow CG Oncology Inc. (CGON) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CGON
Free on the App Store and Google Play, or on the web.